Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 88

1.

Infarct size-limiting effect of epoxyeicosatrienoic acid analog EET-B is mediated by hypoxia-inducible factor-1α via downregulation of prolyl hydroxylase 3.

Neckář J, Hsu A, Hye Khan MA, Gross GJ, Nithipatikom K, Cyprová M, Benák D, Hlaváčková M, Sotáková-Kašparová D, Falck JR, Sedmera D, Kolář F, Imig JD.

Am J Physiol Heart Circ Physiol. 2018 Nov 1;315(5):H1148-H1158. doi: 10.1152/ajpheart.00726.2017. Epub 2018 Aug 3.

PMID:
30074840
2.

A novel activity of microsomal epoxide hydrolase: metabolism of the endocannabinoid 2-arachidonoylglycerol.

Nithipatikom K, Endsley MP, Pfeiffer AW, Falck JR, Campbell WB.

J Lipid Res. 2014 Oct;55(10):2093-102. doi: 10.1194/jlr.M051284. Epub 2014 Jun 23.

3.
4.

Acute and chronic cardioprotection by the enkephalin analogue, Eribis peptide 94, is mediated via activation of nitric oxide synthase and adenosine triphosphate-regulated potassium channels.

Gross GJ, Hsu A, Nithipatikom K, Pfeiffer AW, Bobrova I, Bissessar E.

Pharmacology. 2012;90(1-2):110-6. doi: 10.1159/000340058. Epub 2012 Jul 18.

5.

ROCK1 feedback regulation of the upstream small GTPase RhoA.

Tang AT, Campbell WB, Nithipatikom K.

Cell Signal. 2012 Jul;24(7):1375-80. doi: 10.1016/j.cellsig.2012.03.005. Epub 2012 Mar 11.

6.

Factors mediating remote preconditioning of trauma in the rat heart: central role of the cytochrome p450 epoxygenase pathway in mediating infarct size reduction.

Gross GJ, Hsu A, Gross ER, Falck JR, Nithipatikom K.

J Cardiovasc Pharmacol Ther. 2013 Jan;18(1):38-45. doi: 10.1177/1074248412437586. Epub 2012 Mar 9.

7.

Eribis peptide 94 reduces infarct size in rat hearts via activation of centrally located μ opioid receptors.

Gross GJ, Hsu A, Nithipatikom K, Bobrova I, Bissessar E.

J Cardiovasc Pharmacol. 2012 Feb;59(2):194-7. doi: 10.1097/FJC.0b013e318241e8c7.

8.

Cannabinoid receptor type 1 (CB1) activation inhibits small GTPase RhoA activity and regulates motility of prostate carcinoma cells.

Nithipatikom K, Gomez-Granados AD, Tang AT, Pfeiffer AW, Williams CL, Campbell WB.

Endocrinology. 2012 Jan;153(1):29-41. doi: 10.1210/en.2011-1144. Epub 2011 Nov 15. Erratum in: Endocrinology. 2012 May;153(5):2531.

9.

Protection from myocardial ischemia/reperfusion injury by a positive allosteric modulator of the A₃ adenosine receptor.

Du L, Gao ZG, Nithipatikom K, Ijzerman AP, Veldhoven JP, Jacobson KA, Gross GJ, Auchampach JA.

J Pharmacol Exp Ther. 2012 Jan;340(1):210-7. doi: 10.1124/jpet.111.187559. Epub 2011 Oct 19.

10.

Abdominal surgical incision induces remote preconditioning of trauma (RPCT) via activation of bradykinin receptors (BK2R) and the cytochrome P450 epoxygenase pathway in canine hearts.

Gross GJ, Baker JE, Moore J, Falck JR, Nithipatikom K.

Cardiovasc Drugs Ther. 2011 Dec;25(6):517-22. doi: 10.1007/s10557-011-6321-9.

11.

Role of superoxide and thromboxane receptors in acute angiotensin II-induced vasoconstriction of rabbit vessels.

Pfister SL, Nithipatikom K, Campbell WB.

Am J Physiol Heart Circ Physiol. 2011 Jun;300(6):H2064-71. doi: 10.1152/ajpheart.01135.2010. Epub 2011 Apr 1.

12.

Anti-proliferative effect of a putative endocannabinoid, 2-arachidonylglyceryl ether in prostate carcinoma cells.

Nithipatikom K, Isbell MA, Endsley MP, Woodliff JE, Campbell WB.

Prostaglandins Other Lipid Mediat. 2011 Feb;94(1-2):34-43. doi: 10.1016/j.prostaglandins.2010.12.002. Epub 2010 Dec 15.

13.

Inhibition of carcinoma cell motility by epoxyeicosatrienoic acid (EET) antagonists.

Nithipatikom K, Brody DM, Tang AT, Manthati VL, Falck JR, Williams CL, Campbell WB.

Cancer Sci. 2010 Dec;101(12):2629-36. doi: 10.1111/j.1349-7006.2010.01713.x. Epub 2010 Aug 27.

14.

Evidence for a role of opioids in epoxyeicosatrienoic acid-induced cardioprotection in rat hearts.

Gross GJ, Baker JE, Hsu A, Wu HE, Falck JR, Nithipatikom K.

Am J Physiol Heart Circ Physiol. 2010 Jun;298(6):H2201-7. doi: 10.1152/ajpheart.00815.2009. Epub 2010 Apr 16.

15.

Review article: epoxyeicosatrienoic acids: novel mediators of cardioprotection.

Nithipatikom K, Gross GJ.

J Cardiovasc Pharmacol Ther. 2010 Jun;15(2):112-9. doi: 10.1177/1074248409358408. Epub 2010 Mar 3. Review.

PMID:
20200327
16.

Development of epoxyeicosatrienoic acid analogs with in vivo anti-hypertensive actions.

Imig JD, Elmarakby A, Nithipatikom K, Wei S, Capdevila JH, Tuniki VR, Sangras B, Anjaiah S, Manthati VL, Sudarshan Reddy D, Falck JR.

Front Physiol. 2010 Dec 3;1:157. doi: 10.3389/fphys.2010.00157. eCollection 2010.

17.

Adrenic acid metabolites as endogenous endothelium-derived and zona glomerulosa-derived hyperpolarizing factors.

Kopf PG, Zhang DX, Gauthier KM, Nithipatikom K, Yi XY, Falck JR, Campbell WB.

Hypertension. 2010 Feb;55(2):547-54. doi: 10.1161/HYPERTENSIONAHA.109.144147. Epub 2009 Dec 28.

18.

HPLC/MS/MS-based approaches for detection and quantification of eicosanoids.

Lundström SL, D'Alexandri FL, Nithipatikom K, Haeggström JZ, Wheelock AM, Wheelock CE.

Methods Mol Biol. 2009;579:161-87. doi: 10.1007/978-1-60761-322-0_8.

PMID:
19763475
19.

Identification of 13-hydroxy-14,15-epoxyeicosatrienoic acid as an acid-stable endothelium-derived hyperpolarizing factor in rabbit arteries.

Chawengsub Y, Gauthier KM, Nithipatikom K, Hammock BD, Falck JR, Narsimhaswamy D, Campbell WB.

J Biol Chem. 2009 Nov 6;284(45):31280-90. doi: 10.1074/jbc.M109.025627. Epub 2009 Sep 8.

20.

Evidence for role of epoxyeicosatrienoic acids in mediating ischemic preconditioning and postconditioning in dog.

Gross GJ, Gauthier KM, Moore J, Campbell WB, Falck JR, Nithipatikom K.

Am J Physiol Heart Circ Physiol. 2009 Jul;297(1):H47-52. doi: 10.1152/ajpheart.01084.2008. Epub 2009 May 15.

21.

Soluble epoxide hydrolase: a new target for cardioprotection.

Gross GJ, Nithipatikom K.

Curr Opin Investig Drugs. 2009 Mar;10(3):253-8. Review.

22.

Ceramide elevates 12-hydroxyeicosatetraenoic acid levels and upregulates 12-lipoxygenase in rat primary hippocampal cell cultures containing predominantly astrocytes.

Prasad VV, Nithipatikom K, Harder DR.

Neurochem Int. 2008 Dec;53(6-8):220-9. doi: 10.1016/j.neuint.2008.07.002. Epub 2008 Jul 16.

PMID:
18680775
23.

Roles of Eicosanoids in Prostate Cancer.

Nithipatikom K, Campbell WB.

Future Lipidol. 2008 Aug 1;3(4):453-467.

24.

Expression and function of fatty acid amide hydrolase in prostate cancer.

Endsley MP, Thill R, Choudhry I, Williams CL, Kajdacsy-Balla A, Campbell WB, Nithipatikom K.

Int J Cancer. 2008 Sep 15;123(6):1318-26. doi: 10.1002/ijc.23674.

25.

Angiotensin II relaxations of bovine adrenal cortical arteries: role of angiotensin II metabolites and endothelial nitric oxide.

Gauthier KM, Zhang DX, Cui L, Nithipatikom K, Campbell WB.

Hypertension. 2008 Jul;52(1):150-5. doi: 10.1161/HYPERTENSIONAHA.107.104158. Epub 2008 May 19.

26.

Effects of the selective EET antagonist, 14,15-EEZE, on cardioprotection produced by exogenous or endogenous EETs in the canine heart.

Gross GJ, Gauthier KM, Moore J, Falck JR, Hammock BD, Campbell WB, Nithipatikom K.

Am J Physiol Heart Circ Physiol. 2008 Jun;294(6):H2838-44. doi: 10.1152/ajpheart.00186.2008. Epub 2008 Apr 25.

27.

Structural characterization of monohydroxyeicosatetraenoic acids and dihydroxy- and trihydroxyeicosatrienoic acids by ESI-FTICR.

Cui L, Isbell MA, Chawengsub Y, Falck JR, Campbell WB, Nithipatikom K.

J Am Soc Mass Spectrom. 2008 Apr;19(4):569-85. doi: 10.1016/j.jasms.2008.01.007. Epub 2008 Jan 31.

28.

Identification of 15-hydroxy-11,12-epoxyeicosatrienoic acid as a vasoactive 15-lipoxygenase metabolite in rabbit aorta.

Chawengsub Y, Aggarwal NT, Nithipatikom K, Gauthier KM, Anjaiah S, Hammock BD, Falck JR, Campbell WB.

Am J Physiol Heart Circ Physiol. 2008 Mar;294(3):H1348-56. doi: 10.1152/ajpheart.01326.2007. Epub 2008 Jan 11.

29.

Simultaneous analysis of angiotensin peptides by LC-MS and LC-MS/MS: metabolism by bovine adrenal endothelial cells.

Cui L, Nithipatikom K, Campbell WB.

Anal Biochem. 2007 Oct 1;369(1):27-33. Epub 2007 Jul 5.

30.

Diverse roles of 2-arachidonoylglycerol in invasion of prostate carcinoma cells: Location, hydrolysis and 12-lipoxygenase metabolism.

Endsley MP, Aggarwal N, Isbell MA, Wheelock CE, Hammock BD, Falck JR, Campbell WB, Nithipatikom K.

Int J Cancer. 2007 Sep 1;121(5):984-91.

31.

Mechanisms by which epoxyeicosatrienoic acids (EETs) elicit cardioprotection in rat hearts.

Gross GJ, Hsu A, Falck JR, Nithipatikom K.

J Mol Cell Cardiol. 2007 Mar;42(3):687-91. Epub 2007 Jan 10.

32.

Metabolism of adrenic acid to vasodilatory 1alpha,1beta-dihomo-epoxyeicosatrienoic acids by bovine coronary arteries.

Yi XY, Gauthier KM, Cui L, Nithipatikom K, Falck JR, Campbell WB.

Am J Physiol Heart Circ Physiol. 2007 May;292(5):H2265-74. Epub 2007 Jan 5.

33.

Role of epoxyeicosatrienoic acids in protecting the myocardium following ischemia/reperfusion injury.

Seubert JM, Zeldin DC, Nithipatikom K, Gross GJ.

Prostaglandins Other Lipid Mediat. 2007 Jan;82(1-4):50-9. Epub 2006 Jul 10. Review.

34.

Endothelium-derived steroidogenic factor enhances angiotensin II-stimulated aldosterone release by bovine zona glomerulosa cells.

Hanke CJ, Holmes BB, Xu Y, Nithipatikom K, Campbell WB.

Endocrinology. 2007 Jan;148(1):317-23. Epub 2006 Oct 19.

PMID:
17053027
35.

Chiral resolution of the epoxyeicosatrienoic acids, arachidonic acid epoxygenase metabolites.

Wei S, Brittin JJ, Falck JR, Anjaiah S, Nithipatikom K, Cui L, Campbell WB, Capdevila JH.

Anal Biochem. 2006 May 1;352(1):129-34. Epub 2006 Jan 24.

PMID:
16480681
36.

Epoxyeicosatrienoic acids in cardioprotection: ischemic versus reperfusion injury.

Nithipatikom K, Moore JM, Isbell MA, Falck JR, Gross GJ.

Am J Physiol Heart Circ Physiol. 2006 Aug;291(2):H537-42. Epub 2006 Feb 10.

37.

Reticulocyte 15-lipoxygenase-I is important in acetylcholine-induced endothelium-dependent vasorelaxation in rabbit aorta.

Tang X, Holmes BB, Nithipatikom K, Hillard CJ, Kuhn H, Campbell WB.

Arterioscler Thromb Vasc Biol. 2006 Jan;26(1):78-84. Epub 2005 Oct 20.

PMID:
16239596
38.

Effects of selective inhibition of cytochrome P-450 omega-hydroxylases and ischemic preconditioning in myocardial protection.

Nithipatikom K, Endsley MP, Moore JM, Isbell MA, Falck JR, Campbell WB, Gross GJ.

Am J Physiol Heart Circ Physiol. 2006 Feb;290(2):H500-5. Epub 2005 Oct 7.

39.

Cytochrome P450 and arachidonic acid metabolites: role in myocardial ischemia/reperfusion injury revisited.

Gross GJ, Falck JR, Gross ER, Isbell M, Moore J, Nithipatikom K.

Cardiovasc Res. 2005 Oct 1;68(1):18-25.

PMID:
15993870
40.

A new class of inhibitors of 2-arachidonoylglycerol hydrolysis and invasion of prostate cancer cells.

Nithipatikom K, Endsley MP, Isbell MA, Wheelock CE, Hammock BD, Campbell WB.

Biochem Biophys Res Commun. 2005 Jul 15;332(4):1028-33.

41.

Induction of human cholesterol 7alpha-hydroxylase in HepG2 cells by 2,4,6-trihydroxyacetophenone.

Charoenteeraboon J, Nithipatikom K, Campbell WB, Piyachaturawat P, Wilairat P, Rongnoparut P.

Eur J Pharmacol. 2005 May 16;515(1-3):43-6.

PMID:
15896733
42.

Elevated 12- and 20-hydroxyeicosatetraenoic acid in urine of patients with prostatic diseases.

Nithipatikom K, Isbell MA, See WA, Campbell WB.

Cancer Lett. 2006 Feb 28;233(2):219-25.

PMID:
15882928
43.

Stable 5,6-epoxyeicosatrienoic acid analog relaxes coronary arteries through potassium channel activation.

Yang W, Gauthier KM, Reddy LM, Sangras B, Sharma KK, Nithipatikom K, Falck JR, Campbell WB.

Hypertension. 2005 Apr;45(4):681-6. Epub 2005 Feb 7.

PMID:
15699458
44.

Measurement of steroid synthesis in zona glomerulosa cells by liquid chromatography-electrospray ionization-mass spectrometry: inhibition by nitric oxide.

Nithipatikom K, Holmes BB, Isbell MA, Hanke CJ, Gomez-Sanchez CE, Campbell WB.

Anal Biochem. 2005 Feb 15;337(2):203-10.

PMID:
15691500
45.

2-arachidonoylglycerol: a novel inhibitor of androgen-independent prostate cancer cell invasion.

Nithipatikom K, Endsley MP, Isbell MA, Falck JR, Iwamoto Y, Hillard CJ, Campbell WB.

Cancer Res. 2004 Dec 15;64(24):8826-30.

46.

Cytochrome P450 omega-hydroxylase inhibition reduces infarct size during reperfusion via the sarcolemmal KATP channel.

Gross ER, Nithipatikom K, Hsu AK, Peart JN, Falck JR, Campbell WB, Gross GJ.

J Mol Cell Cardiol. 2004 Dec;37(6):1245-9.

PMID:
15572055
47.

Endothelium-derived 2-arachidonylglycerol: an intermediate in vasodilatory eicosanoid release in bovine coronary arteries.

Gauthier KM, Baewer DV, Hittner S, Hillard CJ, Nithipatikom K, Reddy DS, Falck JR, Campbell WB.

Am J Physiol Heart Circ Physiol. 2005 Mar;288(3):H1344-51. Epub 2004 Nov 4.

48.

Inhibition of cytochrome P450omega-hydroxylase: a novel endogenous cardioprotective pathway.

Nithipatikom K, Gross ER, Endsley MP, Moore JM, Isbell MA, Falck JR, Campbell WB, Gross GJ.

Circ Res. 2004 Oct 15;95(8):e65-71. Epub 2004 Sep 23.

PMID:
15388642
49.

Chronic administration of nitric oxide reduces angiotensin II receptor type 1 expression and aldosterone synthesis in zona glomerulosa cells.

Nithipatikom K, Holmes BB, McCoy MJ, Hillard CJ, Campbell WB.

Am J Physiol Endocrinol Metab. 2004 Nov;287(5):E820-7. Epub 2004 Jun 15.

50.

Cultured rat microglial cells synthesize the endocannabinoid 2-arachidonylglycerol, which increases proliferation via a CB2 receptor-dependent mechanism.

Carrier EJ, Kearn CS, Barkmeier AJ, Breese NM, Yang W, Nithipatikom K, Pfister SL, Campbell WB, Hillard CJ.

Mol Pharmacol. 2004 Apr;65(4):999-1007.

PMID:
15044630

Supplemental Content

Loading ...
Support Center